IFC Advisory is delighted to be working with Midatech Pharma (LSE AIM: MTPH; NASDAQ: MTP) Midatech is an R&D company focused on delivering innovative oncology and rare disease products to patients. The Company is developing a range of improved chemo-therapeutics or new immuno-therapeutics, using its three-proprietary platform drug delivery technologies, all of which are in the clinic.
Client Appointment
Midatech Pharma Appointment
22
Mar
Mar
Feb 2026 : IFC Advisory Expands Digital & Investor Communications Capability
We are delighted to welcome Kelly Lewins to the team. Kelly joins IFC to strengthen [...]
Feb
Feb 2026 : IFC wins Best Financial PR & Investor Relations Agency of the Year – UK in Global 100 : 2026 Awards
February 2026 : IFC wins Best Financial PR & Investor Relations Agency of the Year [...]
Feb
Dec 2025 – IFC advises on $2.4bn takeover of Alphawave Semi
IFC advises on $2.4bn takeover of Alphawave Semi
Dec